Corvus Pharmaceuticals (CRVS) Financials

$14.39

$-0.26 (-1.77%)

As on 04-Sep-2026 17:12EDT

Market cap

$1,211 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

5.3

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.06	0.11	0.09	0.15	0.37	0.46
Gross Profit	-0.06	-0.11	-0.09	-0.15	-0.37	-0.46
Operating Expenses	56.94	42.87	27.55	23.41	32.57	38.63
Operating Profit (EBIT)	-56.96	-42.97	-27.55	-23.41	-32.57	-38.63
Other Income	--	--	--	--	--	--
Profit before Tax	-53.42	-15.28	-62.29	-27.03	-41.31	-43.24
Provision for Tax	0.71	--	--	--	8.74	-5.04
Profit after Tax (Net Income)	-54.13	-15.28	-62.29	-27.03	-41.31	-43.24
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-41.31	-43.24

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	225.33	61.21	32.57	38.68	56.12	97.16
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.27	0.53	0.94	--	1.37	2.60
Current Liabilities	13.67	9.38	35.40	6.87	10.75	9.69
Total Liabilities	252.95	71.12	68.91	45.55	68.24	109.46

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	18.31	12.91	14.50	17.60	24.58	38.14
Current Assets	220.97	58.21	54.41	27.96	43.66	71.31
Total Assets	252.95	71.12	68.91	45.55	68.24	109.46
Total Debt*	0.73	0.94	1.12	1.37	2.60	3.65
Net Current Assets	207.29	48.83	19.01	21.09	32.91	61.62

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-32.80	-25.42	-23.94	-27.02	-36.72
Cash Flow from Investing Activities	--	-7.80	-27.48	15.54	-23.28	21.56
Cash from Financing Activities	--	36.43	49.03	7.86	0.02	62.16
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.62	-0.19	-0.91	-0.55	-0.89	-0.93
Cash EPS ($)	--	-0.19	-0.91	-0.55	-0.88	-0.92
Adjusted Book Value ($)	--	0.77	0.48	0.79	1.21	2.09
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.41	-0.37	-0.49	-0.58	-0.79
Free Cash Flow per Share ($)	--	-0.41	-0.37	-0.49	-0.59	-0.79

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-31.90	-168.93	-54.73	-51.79	-49.34
ROE (%)	-37.78	-32.60	-174.85	-57.02	-53.90	-51.08
ROA (%)	-30.85	-21.83	-108.85	-47.51	-46.49	-44.35
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-14.40	75.47	-130.47	34.57	4.44	1.22
Net Profit Growth (%)	-19.93	75.47	-130.47	34.57	4.47	-796.56
EPS Growth (%)	8.39	0.79	-0.65	0.38	0.04	-4.70
Book Value Growth (%)	136.49	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-40.18	-5.87	-3.19	-0.96	-2.59
Price / Book Value	5.33	10.03	11.23	2.23	0.71	1.15
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.36	-36.78	-5.06	-2.25	0.00	-1.08
Close Price ($)	14.94	7.70	5.35	1.76	0.85	2.41
High Price ($)	26.95	9.60	10.00	4.19	2.51	9.54
Low Price ($)	3.71	2.54	1.30	0.61	0.70	1.86
Market Cap ($ Cr)	1,210.50	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.02	0.03	0.04	0.05	0.04
Short term debt to equity ratio	0.00	0.01	0.01	0.04	0.02	0.01
Current Ratio	16.16	6.21	1.54	4.07	4.06	7.36
Quick Ratio	16.16	--	--	--	4.13	7.43
Interest Coverage	-9.63	-6.10	-34.15	-17.06	-63.16	-2,881.73

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	-1,777.87	-697.66	-460.14
Payable days	--	8,823.40	8,824.01	4,234.24	1,762.06	1,997.76
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.